Equillium Results Presentation Deck
Conclusions from Type A portion of EQUALISE Study
✓ Subcutaneous administration of itolizumab (0.4 - 2.4 mg/kg doses) was well tolerated
Reduced tolerability was observed at the 3.2 mg/kg dose with over 50% of patients discontinuing treatment
after the first dose, 2-3 injections per dose were required
✓ Consistent with the mechanism of action of itolizumab, CD6 on the surface of T cells
decreased significantly in a dose dependent fashion with maximal effect achieved
at doses of 1.6 mg/kg or higher
Exploratory subgroup analysis of Type A SLE subjects with elevated baseline levels of
proteinuria or albuminuria (without diagnosis of active lupus nephritis) showed
a decline in proteinuria - up to 54% - at two months following two doses of itolizumab
✓ The pharmacokinetic and pharmacodynamic analyses and the safety profile observed
to date supports continued evaluation of subcutaneous itolizumab in SLE/ LN
(NCT04128579) and other chronic autoimmune diseases
equillium
Putterman et al., PO1623 & PO1624 ASN, 2021
19View entire presentation